Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | HSD17B14 | Q9BPX1 | 4/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21228090 | 0.87 | CA12 (0.56) | CA9CA14CA12CA1CA2 | |
| SCHEMBL31587898 | 0.86 | CA12 (0.46) | CA9CA14CA12CA1CA2 | |
| SCHEMBL30208191 | 0.86 | CES2 (0.53) | CA9CA14CA12CA1CA2 | |
| SCHEMBL4208340 | 0.86 | CES2 (0.53) | CA9CA14CA12CA1CA2 | |
| SCHEMBL39054 | 0.84 | CA12 (0.63) | CA9CA14CA12CA1CA2 | |
| SCHEMBL4024106 | 0.83 | HTR7 (0.46) | CA9CA14CA12CA1CA2 | |
| SCHEMBL23093930 | 0.81 | ALOX15 (0.50) | CA9CA14CA12CA1CA2 | |
| SCHEMBL4203797 | 0.81 | MAPT (0.48) | CA9CA14CA12CA1CA2 | |
| SCHEMBL30208125 | 0.81 | MAPT (0.48) | CA9CA14CA12CA1CA2 | |
| SCHEMBL2609000 | 0.81 | NOTUM (0.46) | CA9CA14CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| CN-101263107-A | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LAB (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1919854-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2008-05-14 | — | — | EP | disclosed |
| US-7205409-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2007027651-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005023762-A1 | PYRROLIDINE-2-CARBONITRILE DERIVATIVES AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CA9 829/4885CA14 1464/4885CA12 2859/4885 |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CA9 1000/4885CA14 1753/4885CA12 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.